$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
多吉美-肝癌抗癌药
2025-10-19 11:44:20
Check Details
多吉美可延长晚期肝细胞癌总生存期
2025-10-19 11:44:20
Check Details
肝功能损害的患者可以服用索拉非尼吗?
2025-10-19 11:44:20
Check Details
瑞戈非尼治疗肝癌疗效显著
2025-10-19 11:44:20
Check Details
瑞格非尼治疗HCC患者可获得更久的生存期
2025-10-19 11:44:20
Check Details
欧盟批准卡博替尼用于肝癌的二线治疗
2025-10-19 11:44:20
Check Details
乐伐替尼治疗肝癌有效率为37%
2025-10-19 11:44:20
Check Details
多吉美多久会产生耐药性?
2025-10-19 11:44:20
Check Details
卡博替尼晚期肝癌二线治疗选择
2025-10-19 11:44:20
Check Details
瑞格非尼(Regorafenib)肝癌靶向药物
2025-10-19 11:44:20
Check Details
多吉美适应于晚期无法手术的肝癌患者
2025-10-19 11:44:20
Check Details
卡博替尼适应症之肝癌
2025-10-19 11:44:20
Check Details
1
2
...
2558
2559
2560
2561
2562
2563
2564
...
4153
4154
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
2
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
3
Elacestrant: Precision Therapy for ESR1-Mutant Resistant HR+/HER2- Advanced Breast Cancer
4
Selpercatinib Complete Medication Guide: Indications, Dosage and Safety Information for RET Inhibitor
5
Complete Guide to Dosage and Dose Adjustment of Entrectinib
6
Comprehensive Analysis of Bleeding Risk with Tepotinib in MET-Mutated Non-Small Cell Lung Cancer
7
Lomustine vs Temozolomide: Comprehensive Comparison of Efficacy and Safety in Glioma Treatment
8
Tepotinib and Osimertinib: Current Status and Clinical Positioning of Combination Therapy in Non-Small Cell Lung Cancer
9
Tumor Shrinkage Effect and Core Therapeutic Value of Pazopanib
10
Tabrecta (Capmatinib): A Targeted Therapy for METex14-Mutated NSCLC
11
Pazopanib Shows Promise as Second-Line Therapy for Aggressive Skin Cancer
12
Managing Immunotherapy-Related Adverse Events of Tarlatamab-Imdelltra: A Guide to Dual-Specific T Cell Engager Safety